EMAIL THIS PAGE TO A FRIEND

Microvascular research

Oxidative stress modulates nucleobase transport in microvascular endothelial cells.


PMID 24976360

Abstract

Purine nucleosides and nucleobases play key roles in the physiological response to vascular ischemia/reperfusion events. The intra- and extracellular concentrations of these compounds are controlled, in part, by equilibrative nucleoside transporter subtype 1 (ENT1; SLC29A1) and by equilibrative nucleobase transporter subtype 1 (ENBT1). These transporters are expressed at the membranes of numerous cell types including microvascular endothelial cells. We studied the impact of reactive oxygen species on the function of ENT1 and ENBT1 in primary (CMVEC) and immortalized (HMEC-1) human microvascular endothelial cells. Both cell types displayed similar transporter expression profiles, with the majority (>90%) of 2-chloro[(3)H]adenosine (nucleoside) uptake mediated by ENT1 and [(3)H]hypoxanthine (nucleobase) uptake mediated by ENBT1. An in vitro mineral oil-overlay model of ischemia/reperfusion had no effect on ENT1 function, but significantly reduced ENBT1 Vmax in both cell types. This decrease in transport function was mimicked by the intracellular superoxide generator menadione and could be reversed by the superoxide dismutase mimetic MnTMPyP. In contrast, neither the extracellular peroxide donor TBHP nor the extracellular peroxynitrite donor 3-morpholinosydnonimine (SIN-1) affected ENBT1-mediated [(3)H]hypoxanthine uptake. SIN-1 did, however, enhance ENT1-mediated 2-chloro[(3)H]adenosine uptake. Our data establish HMEC-1 as an appropriate model for study of purine transport in CMVEC. Additionally, these data suggest that the generation of intracellular superoxide in ischemia/reperfusion leads to the down-regulation of ENBT1 function. Modification of purine transport by oxidant stress may contribute to ischemia/reperfusion induced vascular damage and should be considered in the development of therapeutic strategies.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

C5134
2-Chloroadenosine
C10H12ClN5O4
A8626
Adenine, ≥99%
C5H5N5
A2786
Adenine, suitable for cell culture, BioReagent
C5H5N5
A5665
Adenine, BioReagent, plant cell culture tested, ≥99%
C5H5N5
A0230000
Adenine, European Pharmacopoeia (EP) Reference Standard
C5H5N5
PHR1383
Adenine, Pharmaceutical Secondary Standard; Certified Reference Material
C5H5N5
Y0000441
Didanosine impurity A,, European Pharmacopoeia (EP) Reference Standard
C5H4N4O
D9766
Dipyridamole, ≥98% (TLC), powder
C24H40N8O4
D2850000
Dipyridamole, European Pharmacopoeia (EP) Reference Standard
C24H40N8O4
Y0000802
Dipyridamole for peak identification, European Pharmacopoeia (EP) Reference Standard
C24H40N8O4
77662
Hypoxanthine, PharmaGrade, Manufactured under appropriate controls for use as a raw material in pharma or biopharmaceutical production.
C5H4N4O
H9377
Hypoxanthine, ≥99.0%
C5H4N4O
H9636
Hypoxanthine, powder, BioReagent, suitable for cell culture
C5H4N4O
458139
Luperox® TBH70X, tert-Butyl hydroperoxide solution, 70 wt. % in H2O
C4H10O2
M5625
Menadione, crystalline
C11H8O2
M9429
Menadione, meets USP testing specifications
C11H8O2
1381006
Menadione, United States Pharmacopeia (USP) Reference Standard
C11H8O2
M0300000
Menadione, European Pharmacopoeia (EP) Reference Standard
C11H8O2
M57405
Menadione, 98%
C11H8O2
PHR1411
Menadione, Pharmaceutical Secondary Standard; Certified Reference Material
C11H8O2
47775
Menadione (K3), analytical standard
C11H8O2
19997
tert-Butyl hydroperoxide solution, packed in FEP bottles, ~5.5 M in decane (over molecular sieve 4Å)
C4H10O2
416665
tert-Butyl hydroperoxide solution, 5.0-6.0 M in decane
C4H10O2
19999
tert-Butyl hydroperoxide solution, packed in FEP bottles, ~5.5 M in nonane (over molecular sieve 4 Å)
C4H10O2
418064
tert-Butyl hydroperoxide solution, 5.0-6.0 M in nonane
C4H10O2